Published in Endocr Rev on April 01, 2003
Effect of DHEA on Skin Aging in Postmenopausal Women | NCT00248989
Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol (2012) 2.99
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol (2013) 1.71
Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer (2008) 1.65
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol (2012) 1.44
Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone. Menopause (2009) 1.42
Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol (2008) 1.36
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol (2011) 1.33
Cytochromes p450 and skin cancer: role of local endocrine pathways. Anticancer Agents Med Chem (2014) 1.20
Sex differences in the physiology of eating. Am J Physiol Regul Integr Comp Physiol (2013) 1.18
Perimenopausal regulation of steroidogenesis in the nonhuman primate. Neurobiol Aging (2011) 1.17
Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element. Nucleic Acids Res (2010) 1.06
Role of androgens and the androgen receptor in remodeling of spine synapses in limbic brain areas. Horm Behav (2007) 1.01
On the role of skin in the regulation of local and systemic steroidogenic activities. Steroids (2015) 1.01
Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod (2009) 0.99
Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nat Rev Endocrinol (2015) 0.97
Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). Eur J Hum Genet (2015) 0.96
Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol (2007) 0.95
Loss of ovarian function in the VCD mouse-model of menopause leads to insulin resistance and a rapid progression into the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol (2009) 0.92
Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Res Treat (2011) 0.92
Estrogens in the breast tissue: a systematic review. Cancer Causes Control (2011) 0.91
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discov (2016) 0.90
Moderate alcohol consumption and breast cancer in women: from epidemiology to mechanisms and interventions. Alcohol Clin Exp Res (2012) 0.90
In situ production of sex steroids in human breast carcinoma. Med Mol Morphol (2007) 0.88
Antiestrogen pathway (aromatase inhibitor). Pharmacogenet Genomics (2009) 0.87
The Role of Androgen Receptor in Breast Cancer. Drug Discov Today Dis Mech (2012) 0.86
Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Womens Health (2010) 0.86
Androgens in human breast carcinoma. Med Mol Morphol (2010) 0.84
Ovarian volumes among women with endometrial carcinoma: associations with risk factors and serum hormones. Gynecol Oncol (2007) 0.84
Androgen deficiency and dry eye syndrome in the aging male. Invest Ophthalmol Vis Sci (2014) 0.82
Association Between Serum Levels of Testosterone and Estradiol With Meibomian Gland Assessments in Postmenopausal Women. Invest Ophthalmol Vis Sci (2016) 0.82
Intrahippocampal Injection of 3α Diol (a Testosterone Metabolite ) and Indomethacin (3α-HSD Blocker), Impair Acquisition of Spatial Learning and Memory in Adult Male Rats. Iran J Pharm Res (2013) 0.81
The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice. FASEB J (2014) 0.81
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res (2014) 0.79
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. Cancers (Basel) (2016) 0.79
Adrenal androgen concentrations increase during infancy in male rhesus macaques (Macaca mulatta). Am J Physiol Endocrinol Metab (2011) 0.78
The Role of Androgens in Normal and Malignant Breast Tissue. Breast Care (Basel) (2008) 0.77
Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer (2012) 0.77
The transdermal patches for site-specific delivery of letrozole: a new option for breast cancer therapy. AAPS PharmSciTech (2010) 0.77
CYP17 and breast cancer: no overall effect, but what about interactions? Breast Cancer Res (2005) 0.77
Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy. Curr Breast Cancer Rep (2014) 0.76
Effect of sex steroids and insulin on dehydroepiandrosterone sulfate production by hepatoma G2 cells. Fertil Steril (2008) 0.76
Low salivary testosterone levels in patients with breast cancer. BMC Cancer (2010) 0.76
Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. Fertil Steril (2007) 0.76
Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor. Oncotarget (2016) 0.75
AR Signaling in Breast Cancer. Cancers (Basel) (2017) 0.75
Expression and localization of estrogenic type 12 17beta-hydroxysteroid dehydrogenase in the cynomolgus monkey. BMC Biochem (2007) 0.75
Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer. Breast Cancer Res (2015) 0.75
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer. Menopause (2014) 0.75
Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Sci (2014) 0.75
Sex-specific effects of serum sulfate level and SLC13A1 nonsense variants on DHEA homeostasis. Mol Genet Metab Rep (2017) 0.75
Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk. Horm Cancer (2016) 0.75
Human 3β-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations. Cancer Med (2016) 0.75
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur J Hum Genet (2006) 5.34
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate (2004) 4.02
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol (2006) 2.81
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Quantitative trait loci mapping in five new large recombinant inbred line populations of Arabidopsis thaliana genotyped with consensus single-nucleotide polymorphism markers. Genetics (2008) 2.17
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos (2003) 1.72
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
HLM1, an essential signaling component in the hypersensitive response, is a member of the cyclic nucleotide-gated channel ion channel family. Plant Cell (2003) 1.66
Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab (2008) 1.58
Genetic discrimination and life insurance: a systematic review of the evidence. BMC Med (2013) 1.55
Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev (2007) 1.53
Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause (2009) 1.52
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites. EMBO Rep (2002) 1.44
The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology (2003) 1.42
The meiotic protein SWI1 is required for axial element formation and recombination initiation in Arabidopsis. Development (2003) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Natural variation in Arabidopsis thaliana as a tool for highlighting differential drought responses. PLoS One (2008) 1.33
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res (2005) 1.31
Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab (2003) 1.31
Regulation of the human cyclin-dependent kinase inhibitor p18INK4c by the transcription factors E2F1 and Sp1. J Biol Chem (2002) 1.30
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol (2006) 1.29
Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol (2009) 1.26
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2009) 1.25
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. Biochem J (2002) 1.23
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res (2003) 1.21
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab (2007) 1.19
UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem (2007) 1.18
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
A high throughput genetic screen identifies new early meiotic recombination functions in Arabidopsis thaliana. PLoS Genet (2009) 1.16
Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol (2008) 1.16
Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res (2004) 1.12
Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem (2008) 1.11
Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J Mol Biol (2003) 1.11
Androgen metabolism in adipose tissue: recent advances. Mol Cell Endocrinol (2008) 1.10
Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev (2005) 1.08
Genetic analysis of two Arabidopsis DNA polymerase epsilon subunits during early embryogenesis. Plant J (2005) 1.07
Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. Genet Test (2007) 1.07
The Arabidopsis MEI1 gene encodes a protein with five BRCT domains that is involved in meiosis-specific DNA repair events independent of SPO11-induced DSBs. Plant J (2003) 1.06
Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause (2009) 1.06
Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling. J Steroid Biochem Mol Biol (2008) 1.06
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause (2009) 1.06
The endosperm and the embryo of Arabidopsis thaliana are independently transformed through infiltration by Agrobacterium tumefaciens. Transgenic Res (2003) 1.05
17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol (2010) 1.05
Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. Mol Endocrinol (2004) 1.05
No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiol Biomarkers Prev (2005) 1.04
AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells. Cancer Res (2002) 1.04
Urotensin II, from fish to human. Ann N Y Acad Sci (2010) 1.04
Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf) (2009) 1.04
Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation. J Biol Chem (2004) 1.04
Identifying androsterone (ADT) as a cognate substrate for human dehydroepiandrosterone sulfotransferase (DHEA-ST) important for steroid homeostasis: structure of the enzyme-ADT complex. J Biol Chem (2003) 1.03
Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases. Urology (2007) 1.03
Biochemical and functional characterization of ORF138, a mitochondrial protein responsible for Ogura cytoplasmic male sterility in Brassiceae. Biochimie (2005) 1.03
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J Hum Genet (2008) 1.02
Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol (2006) 1.02
Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene. Mol Cancer (2003) 1.02
Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocr Res (2004) 1.02
Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate (2003) 1.01
The putative Arabidopsis homolog of yeast vps52p is required for pollen tube elongation, localizes to Golgi, and might be involved in vesicle trafficking. Plant Physiol (2004) 1.01
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
The crystal structure of human Delta4-3-ketosteroid 5beta-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism. Biochemistry (2008) 1.00
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet (2013) 1.00
The ternary structure of the double-headed arrowhead protease inhibitor API-A complexed with two trypsins reveals a novel reactive site conformation. J Biol Chem (2009) 0.99
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. Mol Endocrinol (2005) 0.98
Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue. J Steroid Biochem Mol Biol (2010) 0.97
Quantitative appreciation of steroidogenic gene expression in mouse tissues: new roles for type 2 5alpha-reductase, 20alpha-hydroxysteroid dehydrogenase and estrogen sulfotransferase. J Steroid Biochem Mol Biol (2005) 0.96
Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem (2008) 0.96
The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2006) 0.96
Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem (2006) 0.95